For the eighth consecutive year, Cure SMA has received a grant from the National Institutes of Health (NIH) for the SMA Researcher Meeting. This year’s grant will go toward conference expenses for graduate students and fellows, who are younger researchers in training. With the help of this NIH grant, Cure SMA generously subsidizes the cost […]
Cure SMA Receives 2016 NIH Grant Read More »
Cure SMA is pleased to announce that Biogen will be the Presenting Sponsor for our 2016 Annual SMA Conference. This year’s conference is set to be a significant event for the SMA community, with over 1,400 families and researchers coming together in Disneyland, June 16-19. “Without the generosity and support of Biogen, it would not
Cure SMA Announces Biogen as Presenting Sponsor for the 2016 Annual SMA Conference Read More »
We’ve recently released an update to the SMA drug pipeline. This latest version includes: 18 active programs. 14 pharmaceutical partners. 6 programs in clinical trials. 28 programs in the cumulative pipeline total, including 10 failures to date. An ever-increasing breadth of potential treatment approaches to SMA. Effective Treatments for All Ages, Stages and Types of
Cure SMA Releases June 2016 Update to the SMA Drug Pipeline Read More »
Thank you to the following exhibitors who have generously supported our 2016 Annual SMA Conference. This one-of-a-kind event would not be possible without your support! For more information on any of these companies, please visit our conference exhibitor page. Conference Exhibitors Platinum Exhibitors Gold Exhibitors Gunnell, Inc. Innovation In Motion PromptCare RespirTechThomashilfen North America Triumph
Thank you to Our 2016 Annual SMA Conference Exhibitors! Read More »
Biogen and Ionis Pharmaceuticals recently provided an update on the clinical development of nusinersen (IONIS-SMNRx), which is currently being tested in Phase 3 clinical trials: Dear members of the SMA community, As we approach the upcoming Cure SMA conference in Anaheim, we want to provide an update on the status of the nusinersen program and
Biogen and Ionis Release Spring 2016 Community Update Read More »
The SMA drug pipeline has grown dramatically in just over a decade. Of the 18 programs in the pipeline, six of these are in clinical trials, and several of those are in Phase 2 and Phase 3 clinical trials. Reaching and achieving FDA approval is a major step in our path to a treatment and
2016 Update on SMA-FDA Interactions Read More »
The 2016 Annual SMA Conference Booklet has been posted. The booklet includes: A complete schedule with information about the special events we’ve got planned for each evening including: the Meet and Greet and Family Fun Fest, the Family Friendly Research Poster Session, and Saturday Night at Disneyland Park! Information on Saturday afternoon’s panels focusing on
2016 Annual SMA Conference Booklet Now Posted Read More »
Novartis recently provided the following update on clinical trials for LMI070, an orally available SMA drug that corrects SMN2 splicing: “We have made the difficult decision to pause enrollment for our study of LMI070 for the treatment of Type 1 Spinal Muscular Atrophy (SMA). Animal safety studies were taking place in parallel with this trial,
Update on the Clinical Development of LMI070 Read More »
The Spring 2016 issue of Compass is now available online. As part of our most recent round of funding, we’ve announced eight grants totaling $890,000 for basic research, and two grants totaling $100,000 for clinical care research. This issue introduces our ten grantees and gives background on each of their projects: what the project is,
Spring 2016 Issue of Compass Now Available Read More »
Cure SMA has awarded a $300,000 drug discovery grant to Charlotte Sumner, MD, at Johns Hopkins University, in collaboration with Imago Pharmaceuticals. The award is for the project, “Preclinical Development of a JNK Drug Candidate to Alter Disease Progression in SMA.” The Importance of Combination Therapies As the SMA drug pipeline has grown in breadth,
